c-Myc
Los inhibidores de c-Myc se dirigen a la proteína c-Myc, un factor de transcripción que juega un papel crucial en el crecimiento celular, la proliferación y la apoptosis. c-Myc regula la expresión de numerosos genes involucrados en el ciclo celular y a menudo está sobreexpresado en varios tipos de cáncer, lo que lleva a una proliferación celular descontrolada y al crecimiento tumoral. Inhibir c-Myc puede interrumpir estos procesos, induciendo el arresto del ciclo celular y la apoptosis en células cancerosas. Los inhibidores de c-Myc son herramientas importantes en la investigación del cáncer y el desarrollo terapéutico. En CymitQuimica, ofrecemos una amplia gama de inhibidores de c-Myc de alta calidad para apoyar su investigación en oncología, regulación del ciclo celular y control transcripcional.
Se han encontrado 69 productos de "c-Myc"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
MYCi361
CAS:<p>MYCi361 (NUCC-0196361) is an inhibitor of MYC (binding to MYC with Kd of 3.2 μM).</p>Fórmula:C26H16ClF9N2O2Pureza:99.52%Forma y color:SolidPeso molecular:594.86MYCi975
CAS:<p>MYCi975 (NUCC-0200975) is an orally active inhibitor of MYC.</p>Fórmula:C25H16Cl2F6N2O2Pureza:99.3% - 99.82%Forma y color:SolidPeso molecular:561.3Eragidomide
CAS:<p>Eragidomide (Cereblon modulator 1) is a CRBN E3 ligase modulator, specifically binds to CRBN, thereby affecting the activity of the ubiquitin E3 ligase complex.</p>Fórmula:C22H18ClF2N3O4Pureza:97.51% - 99.63%Forma y color:SolidPeso molecular:461.85Ceramides Mixture
CAS:<p>Ceramides Mixture: endogenous, regulates cell cycle, growth, and telomerase activity, with hydroxy/non-hydroxy fatty acids.</p>Fórmula:C36H71NO4Pureza:98%Forma y color:SolidPeso molecular:581.967APTO-253
CAS:<p>APTO-253 (LOR-253) inhibits c-Myc expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells.</p>Fórmula:C22H14FN5Pureza:98.73%Forma y color:SolidPeso molecular:367.38MYCMI-6
CAS:<p>MYCMI-6 inhibits MYC:MAX, reduces tumor growth, triggers apoptosis, minimal side effects.</p>Fórmula:C20H19N7OPureza:99.23%Forma y color:SolidPeso molecular:373.41KJ Pyr 9
CAS:<p>KJ Pyr 9 is an MYC inhibitor (Kd: 6.5 nM in vitro assay).</p>Fórmula:C22H15N3O4Pureza:99.56% - ≥98%Forma y color:SolidPeso molecular:385.37FIDAS-3
CAS:<p>FIDAS-3, a stilbene derivative and potent Wnt inhibitor with an IC50 of 4.9 μM for methionine S-adenosyltransferase 2A (MAT2A), exhibits anticancer activities</p>Fórmula:C16H15F2NPureza:97.75%Forma y color:SolidPeso molecular:259.29FIDAS-5
CAS:<p>FIDAS-5 is an orally active methionine adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM. Cost-effective and quality-assured.</p>Fórmula:C15H13ClFNPureza:97.66% - 98.3%Forma y color:SolidPeso molecular:261.72Saxagliptin hydrate
CAS:<p>Saxagliptin hydrate (Onglyza hydrate) is a selective and reversible DPP4 inhibitor (IC50: 26 nM; Ki: 1.3 nM).</p>Fórmula:C18H25N3O2·H2OPureza:99.52%Forma y color:SolidPeso molecular:333.43MYC-IN-2
CAS:<p>MYC-IN-2 is a protein-protein inhibitor targeting the MYC protein, designed for use in cancer research.</p>Fórmula:C25H17N3O2SForma y color:SolidPeso molecular:423.49RA-V
<p>RA-V is a natural product that can be used as a reference standard.</p>Fórmula:C160H202N24O41Forma y color:SolidPeso molecular:3117.5c-Myc inhibitor 5
<p>DA3: Fluorescent c-Myc inhibitor, targets c-MYC G-quadruplex (K D 16 μM), selective, suppresses c-MYC expression.</p>Fórmula:C30H46N12Forma y color:SolidPeso molecular:574.77c-Myc inhibitor 10
CAS:<p>c-Myc inhibitor 10 enhances cell potency with improved permeability from methylated morpholine nitrogen.</p>Fórmula:C28H38N6O3Forma y color:SolidPeso molecular:506.64c-Myc inhibitor 12
<p>Compound 67h, also known as c-Myc inhibitor 12, is a potent inhibitor of c-Myc, exhibiting a pEC50 value of 6.4 [1].</p>Fórmula:C22H24N6OPureza:98%Forma y color:SolidPeso molecular:388.47MDEG-541
<p>MDEG-541 is a potent MYC-MAX degrader that exhibits antiproliferative activity by downregulating the expression of GSPT1, MYC, GSPT2, and PLK1 proteins [1].</p>Fórmula:C35H38N4O7SPureza:98%Forma y color:SolidPeso molecular:658.76Anti-c-myc Antibody (9E10)
<p>Anti-c-myc Antibody (9E10) is a chimeric mouse IgG1 antibody targeting human c-myc.</p>Forma y color:Odour LiquidPROTAC MTP3 degrade-1
<p>PROTACMTP3 degrade-1 is a PROTAC degrader for MYC.</p>Fórmula:C44H38N6O8Forma y color:SolidPeso molecular:778.27511Methylcarbamyl PAF C-8
<p>Methylcarbamyl PAF C-8 is resistant to degradation by PAF-AH and has a half-life of over 100 minutes in platelet-poor plasma, exhibiting platelet aggregation activity. In NRK-49 cells overexpressing PAF receptor, it induces the expression of c-myc, c-fos, and activates mitogen-activated protein kinase (MAPK). Furthermore, Methylcarbamyl PAF C-8 can induce G1 phase cell cycle arrest. This compound shows potential for research in cardiovascular and anti-cancer applications.</p>Forma y color:Odour Solidc-Myc inhibitor 11
<p>c-Myc inhibitor 11 (Compound 67e), a c-MYC inhibitor (p EC 50 : 6.4), exhibits high clearance, a moderate volume of distribution, and a short half-life in rat</p>Fórmula:C20H22N6OPureza:98%Forma y color:SolidPeso molecular:362.43CSI86
<p>CSI86 is a PROTAC degrader targeting MYC, exhibiting antiproliferative activity (IC50: 13-18 μM).</p>Fórmula:C48H50F9N7O7SForma y color:SolidPeso molecular:1040WBC100
CAS:<p>WBC100 (14-D-Valine-TPL) is a potent, selective, and orally active c-Myc glue degrader that targets the ubiquitin E3 ligase CHIP-mediated 26S proteasome pathway</p>Fórmula:C25H33NO7Pureza:98%Forma y color:SolidPeso molecular:459.53Anticancer agent 263
<p>Anticanceragent 263 (compound 7) is an effective anticancer agent. It binds with the G-quadruplex DNA (G4) sequence 22-mer Pu22 (a c-Myc DNA analog). As a structural modulator, Anticanceragent 263 significantly enhances the formation of protein α-helices and has the capacity to form a supramolecular network. Furthermore, Anticanceragent 263 exhibits no cytotoxicity.</p>Fórmula:C13H20N2O6Forma y color:SolidPeso molecular:300.308c-Myc inhibitor 7
CAS:<p>c-Myc inhibitor 7 degrades c-MYC, CK1α, GSPT1, IKZF1/2/3 proteins in tumors, for research on related diseases.</p>Fórmula:C35H30N6O5Forma y color:SoildPeso molecular:614.65Anticancer agent 84
CAS:<p>Anticancer agent 84 inhibits c-MYC transcription by stabilizing G4 structures, aiding cancer research.</p>Fórmula:C57H67N7O9Forma y color:SolidPeso molecular:994.18VGN50
<p>VGN50 is a bioactive molecule that mimics the function of K-Rta, capable of downregulating MYC-mediated gene transcription. VGN50 exhibits antitumor activity.</p>Fórmula:C121H218N46O32Peso molecular:2827.68453c-Myc inhibitor 13
<p>c-Myc inhibitor13 (compound A6) is an inhibitor of c-MYC transcription. It selectively stabilizes c-MYCG4 and inhibits G4-related c-MYC transcription.</p>Fórmula:C30H39N9OPeso molecular:541.32776Cotylenin A
CAS:<p>Cotylenin A is a phenanthraquinone compound that synergistically works with vitamin K2 to induce monocyte differentiation and growth arrest. It also inhibits c-Myc expression while inducing cyclin G2 expression in human leukemia HL-60 cells. Cotylenin A is applicable in acute myeloid leukemia research.</p>Fórmula:C33H50O11Forma y color:SolidPeso molecular:622.744H122
<p>H122 is a TEADPROTAC degrader effective in degrading TEAD1 with a DC50 of 3 nM, and it shows strong affinity for TEAD2, TEAD3, and TEAD4 with Ki values of 2.0, 3.6, and 1.6 nM, respectively. H122 also downregulates Myc expression and inhibits the growth of MSTO-211H and NCI-H226 cells, with IC50 values of 21.3 nM and 0.6 nM, respectively, demonstrating antitumor activity in mouse models. (Pink: ligand for target protein; Black: linker; Blue: ligand for E3 ligaseCereblon)</p>Fórmula:C45H45ClFN5O8Forma y color:SolidPeso molecular:838.319PROTAC LZK-IN-1
CAS:<p>PROTAC LZK-IN-1 (Compound 21A) is a PROTAC molecule that targets the degradation of LZK (leucine zipper kinase, encoded by MAP3K13). At a concentration of 10 μM, PROTAC LZK-IN-1 facilitates the degradation of LZK and inhibits the expression of p53 and c-MYC, leading to reduced viability of global head and neck squamous cell carcinoma (HNSCC) cell lines. This compound is applicable in anticancer research.</p>Fórmula:C51H64F2N10O5SForma y color:SolidPeso molecular:967.18KL4-219A
<p>KL4-219A is a selective covalent degrader of the MYC, inhibiting MYC transcriptional activity and degrading MYC in a proteasome-dependent manner .</p>Fórmula:C20H24N2O2SPureza:99.68%Forma y color:SolidPeso molecular:356.48VPC-70063
CAS:<p>VPC-70063 (Thiourea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-(phenylmethyl)-) is an inhibitor of c-Myc-MAX.</p>Fórmula:C16H12F6N2SPureza:99.98%Forma y color:SolidPeso molecular:378.34sAJM589
CAS:<p>sAJM589 is a Myc inhibitor that dose-dependently disrupts Myc-Max heterodimers, thereby decreasing Myc protein levels and inhibiting the cellular proliferation.</p>Fórmula:C16H10N2OPureza:98%Forma y color:SolidPeso molecular:246.26IRES-C11
CAS:<p>IRES-C11 is a specific inhibitor of translation that targets the internal ribosome entry site (IRES) of the c-MYC gene. It functions by blocking the interaction between heterogeneous nuclear ribonucleoprotein A1, a trans-acting factor required for c-MYC IRES activity, and its corresponding IRES. Notably, IRES-C11 does not inhibit the IRES activity of BAG-1, XIAP, and p53.</p>Fórmula:C13H11Cl2NO4Pureza:99.89%Forma y color:SolidPeso molecular:316.14Mycro 3
CAS:<p>Mycro 3 is potent and selective for c-Myc in whole cell assays.</p>Fórmula:C24H17ClF2N6O4Pureza:99.51% - 99.61%Forma y color:SolidPeso molecular:526.88Saxagliptin
CAS:<p>Saxagliptin (BMS-477118) is a selective and reversible DPP4 inhibitor with IC50 of 26 nM.</p>Fórmula:C18H25N3O2Pureza:99.17% - 99.95%Forma y color:SolidPeso molecular:315.41(S)-10-Hydroxycamptothecin
CAS:<p>(S)-10-Hydroxycamptothecin (10-HCPT) is a DNA topoisomerase I inhibitor, utilized as a clinical therapy agent against hepatoma.</p>Fórmula:C20H16N2O5Pureza:99.09% - 99.81%Forma y color:SolidPeso molecular:364.35Mollugin
CAS:<p>Mollugin could be a JAK2 inhibitor, anti-inflammatory, chemotherapeutic agent in OSCCs, bone disorder therapy, and modulates HER2 in cancer.</p>Fórmula:C17H16O4Pureza:99.87% - ≥95%Forma y color:SolidPeso molecular:284.31ML327
CAS:<p>ML327 is a MYC blocker. ML327 can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT).</p>Fórmula:C19H18N4O4Pureza:98.47%Forma y color:SolidPeso molecular:366.3710074-G5
CAS:<p>10074-G5 is an inhibitor of c-Myc-Max dimerization.</p>Fórmula:C18H12N4O3Pureza:99.51% - 99.67%Forma y color:SolidPeso molecular:332.31NNK
CAS:<p>NNK is a procarcinogen and a major tobacco-specific toxicant. It inhibits the expression of lysyl oxidase which is a tumor suppressor.Cost-effective and quality-assured.</p>Fórmula:C10H13N3O2Pureza:99.63% - 99.92%Forma y color:SolidPeso molecular:207.23Lusianthridin
CAS:<p>Lusianthridin is a natural product from Dendrobium venustum.</p>Fórmula:C15H14O3Pureza:98.49%Forma y color:SolidPeso molecular:242.27Agrimol B
CAS:<p>1. Agrimol B is a main active ingredient isolated from Agrimonia pilosa Ledeb.</p>Fórmula:C37H46O12Pureza:99.06% - ≥95%Forma y color:SolidPeso molecular:682.7510058-F4
CAS:<p>10058-F4 inhibits c-Myc-Max, blocking c-Myc target gene activation, causing cell-cycle arrest & apoptosis.</p>Fórmula:C12H11NOS2Pureza:98% - 99.87%Forma y color:SolidPeso molecular:249.35APTO-253 HCl
CAS:<p>APTO-253 (LOR-253/LT-253) is a small-molecule MTF-1 inhibitor with antitumor properties, reducing cyclin D1, hypoxia, and angiogenesis gene expression.</p>Fórmula:C22H15ClFN5Forma y color:SolidPeso molecular:403.8410074-A4
CAS:<p>10074-A4 is a c-Myc binding compound that associates with c-Myc370–409 and behaves like a “ligand cloud” around a “protein cloud”, with distinct features from</p>Fórmula:C18H14Cl2N2O3SPureza:99.06%Forma y color:SolidPeso molecular:409.29Artemisitene
CAS:<p>Artemisitene, an oxidized antimalarial derivative of Artemisinin, stems from precursors like Artemisinin B and Artemisinic acid.</p>Fórmula:C15H20O5Pureza:99.58%Forma y color:SolidPeso molecular:280.32NY2267
CAS:<p>NY2267 (Acetic acid, 2-[[6-[2-(cyclohexylamino)-1-[[(4-methoxyphenyl)methyl](2-pyridinylcarbonyl)amino]-2-oxoethyl]-2-naphthalenyl]oxy]-, 1,1-dimethylethyl</p>Fórmula:C38H43N3O6Pureza:99.16% - 99.27%Forma y color:SolidPeso molecular:637.76Idarubicin hydrochloride
CAS:<p>Idarubicin hydrochloride (Zavedos), a hydrochloride salt form of Idarubicin, is a DNA topoisomerase II (topo II) inhibitor for MCF-7 cells ( IC50: 3.3 ng/mL).</p>Fórmula:C26H27NO9·HClPureza:98.91% - 99.96%Forma y color:SolidPeso molecular:533.95BTYNB
CAS:<p>BTYNB (MDK6620) is an inhibitor of the oncofetal mRNA-binding protein IMP1. MDK6620 downregulates β-TrCP1 mRNA and reduces activation of NF-κB.</p>Fórmula:C12H9BrN2OSPureza:≥95%Forma y color:SolidPeso molecular:309.18EN4
CAS:<p>EN4 (EN4 MYC inhibitor) MYC inhibitor is a covalent ligand that targets cysteine 171 (C171) of MYC.</p>Fórmula:C25H24N2O4Pureza:98.51%Forma y color:SolidPeso molecular:416.47PARL Protein, Human, Recombinant (Myc)
<p>Required for the control of apoptosis during postnatal growth.</p>Forma y color:Lyophilized PowderPeso molecular:37.8 kDa (predicted)ACOX1 Protein, Mouse, Recombinant (Myc)
<p>Catalyzes the desaturation of acyl-CoAs to 2-trans-enoyl-CoAs.</p>Forma y color:Lyophilized PowderPeso molecular:76.2 kDa (predicted)2-5A-dependent Rnase Protein, Human, Recombinant (Myc)
<p>2-5A-dependent Rnase Protein, Human, Recombinant (Myc) is expressed in E.</p>Pureza:85% - 85%Forma y color:Lyophilized PowderPeso molecular:85.1 kDa (predicted)c-Myc inhibitor 9
CAS:<p>c-Myc inhibitor 9 (compound 332) with logEC50 ≥6, suppresses tumors in mice, useful for cancer research.</p>Fórmula:C27H31N5OSForma y color:SolidPeso molecular:473.63RK-9123016
CAS:<p>RK-9123016 is a SIRT2 inhibitor.</p>Fórmula:C16H18N6O3SPureza:99.65%Forma y color:SolidPeso molecular:374.42FUBP1-IN-2
CAS:<p>FUBP1-IN-2 hinders FUBP1, affects c-Myc and p21 expression, and depletes polyamines.</p>Fórmula:C26H26ClN3O4Forma y color:SolidPeso molecular:479.96KSI-3716
CAS:<p>KSI-3716 is a c-Myc inhibitor, a bladder chemotherapy agent that blocks the formation of complexes between c-MYC/MAX and target gene promoters.</p>Fórmula:C17H11BrCl2N2O2Pureza:98.94%Forma y color:SolidPeso molecular:426.09BI8622
CAS:<p>BI8622 is a HUWE1 antagonist that restores levels of RP2 mutants in retinal cell lines and inhibits cellular activation of NLRP3 and AIM2 inflammatory vesicles.</p>Fórmula:C25H26N6OPureza:98.28%Forma y color:SolidPeso molecular:426.51VPC-70619
CAS:<p>VPC-70619: Oral, selective N-Myc inhibitor; blocks cancer growth by hindering N-Myc-Max/DNA binding; well-absorbed.</p>Fórmula:C16H8ClF3N4OForma y color:SolidPeso molecular:364.71c-Myc inhibitor 8
CAS:<p>c-Myc inhibitor 8 suppresses cell growth in various cancers and is used in research.</p>Fórmula:C19H12BrClF3NO3S2Forma y color:SolidPeso molecular:538.79m-Se3
CAS:<p>m-Se3 is a potent, selective inhibitor of c-MYC transcription with demonstrated capability to inhibit tumor growth and exhibit anti-cancer activity [1].</p>Fórmula:C29H23IN2SePureza:98%Forma y color:SolidPeso molecular:605.37SYHA1815
CAS:<p>SYHA1815, an orally active RET inhibitor (IC50=0.9 nmol/L), demonstrates antitumor activity. It exhibits greater selectivity for RET over KDR (IC50=15.9 nmol/L). SYHA1815 operates by downregulating c-Myc, arresting the G1 cell cycle, and inhibiting RET-driven cell proliferation.</p>Fórmula:C27H26ClF4N5OForma y color:SolidPeso molecular:547.98KI-CDK9d-32
CAS:<p>KI-CDK9d-32 is a CDK9 PROTAC degrader with a DC50 of 0.89 nM. It facilitates the ubiquitination and degradation of CDK9, inhibits the MYC pathway, and disrupts nucleolar homeostasis. KI-CDK9d-32 demonstrates anticancer activity.</p>Fórmula:C39H45N9O4Forma y color:SolidPeso molecular:703.83c-Myc inhibitor 4
<p>Potent oral c-Myc inhibitor 4 reduces the proto-oncogene linked to tumor development.</p>Fórmula:C26H33FN6O3Forma y color:SolidPeso molecular:496.58BRD4 Inhibitor-40
CAS:<p>BRD4 Inhibitor-40 (Compound 23) functions as an inhibitor of BRD, effectively targeting BRD4-BD1, BRD4-BD2, BRD2-BD1, and BRD2-BD2, with IC50 values of 16.1, 142.18, 29.35, and 302.35 nM, respectively. It modulates the expression of c-Myc and p21, induces cell cycle arrest in the G1 phase, and inhibits Pkd1-deficient (PN) renal cystic epithelial cells. Additionally, it prevents renal cyst formation in both Madin-Darby canine kidney and embryonic kidney cyst models, and demonstrates renal cyst inhibition activity in mouse models.</p>Fórmula:C27H32N8OForma y color:SolidPeso molecular:484.596MY05
CAS:<p>MY05 selectively targets c-MYC within cells and disrupts the interaction between MYC and MAX. It binds to intracellular c-MYC, modulating its thermal stability, reducing the transcriptional targets of c-MYC, and exhibiting anticancer activity (TNBC, triple-negative breast cancer).</p>Fórmula:C19H11ClN4OForma y color:SolidPeso molecular:346.77JY-3-094
CAS:<p>JY-3-094 is a selective Myc inhibitor that targets the hydrophobic domain of Myc and inhibits the formation of the Myc-Max heterodimer, with an IC50 of 33 μM, and can be used for cancer research.</p>Fórmula:C13H8N4O5Pureza:98.72%Forma y color:SolidPeso molecular:300.23β-catenin-IN-8
CAS:<p>β-catenin-IN-8 (Compound 25) is an inhibitor of β-catenin. It effectively lowers the levels of both β-catenin and c-Myc proteins and suppresses Wnt target genes (Fgf20 and Sall4). Additionally, β-catenin-IN-8 exhibits anticancer activity against colorectal cancer and possesses metabolic stability.</p>Fórmula:C15H12ClN3O2SForma y color:SolidPeso molecular:333.79
